# A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma

> **NCT01672450** · PHASE1 · COMPLETED · sponsor: **University of Utah** · enrollment: 12 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Intratumoral Ipilimumab and Interleukin-2

## Key facts

- **NCT ID:** NCT01672450
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2015-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01672450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01672450, "A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01672450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*